[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

In8Bio Inc (INAB)

In8Bio Inc (INAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,081
  • Shares Outstanding, K 9,847
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,440 K
  • EBIT $ -19 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.61
  • Number of Estimates 1
  • High Estimate $-0.61
  • Low Estimate $-0.61
  • Prior Year $-1.24
  • Growth Rate Est. (year over year) +50.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3220 +8.17%
on 06/11/26
1.8800 -23.94%
on 05/29/26
+0.0100 (+0.70%)
since 05/18/26
3-Month
1.3100 +9.16%
on 04/15/26
2.0300 -29.56%
on 03/20/26
-0.4100 (-22.28%)
since 03/18/26
52-Week
1.1700 +22.22%
on 12/19/25
2.7300 -47.62%
on 01/16/26
-0.7000 (-32.86%)
since 06/18/25

Most Recent Stories

More News
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs)...

INAB : 1.4300 (-2.72%)
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached)....

INAB : 1.4300 (-2.72%)
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma...

INAB : 1.4300 (-2.72%)
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care;...

INAB : 1.4300 (-2.72%)
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”)...

INAB : 1.4300 (-2.72%)
RedChip's Biotech Virtual Investor Conference Replays Now Available

ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

CLDI : 0.1689 (+11.12%)
INAB : 1.4300 (-2.72%)
DMAC : 5.85 (+2.09%)
NSRX : 3.07 (-0.32%)
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

CLDI : 0.1689 (+11.12%)
INAB : 1.4300 (-2.72%)
CNTB : 2.00 (-3.85%)
DMAC : 5.85 (+2.09%)
NSRX : 3.07 (-0.32%)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune...

INAB : 1.4300 (-2.72%)
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy...

INAB : 1.4300 (-2.72%)
IN8bio to Present at TD Cowen 46th Annual Health Care Conference

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune...

INAB : 1.4300 (-2.72%)

Business Summary

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.5467
2nd Resistance Point 1.5233
1st Resistance Point 1.4767
Last Price 1.4300
1st Support Level 1.4067
2nd Support Level 1.3833
3rd Support Level 1.3367

See More

52-Week High 2.7300
Fibonacci 61.8% 2.1341
Fibonacci 50% 1.9500
Fibonacci 38.2% 1.7659
Last Price 1.4300
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.